首页 | 本学科首页   官方微博 | 高级检索  
检索        

胰激肽原酶加厄贝沙坦治疗早期糖尿病肾病的疗效观察
引用本文:李桃荣,宁尚侠,李建英.胰激肽原酶加厄贝沙坦治疗早期糖尿病肾病的疗效观察[J].中国药业,2013(22):26-27.
作者姓名:李桃荣  宁尚侠  李建英
作者单位:湖北省荆州市中心医院,湖北荆州434020
摘    要:目的观察胰激肽原酶加厄贝沙坦治疗2型糖尿病早期肾病的疗效。方法90例患者维持糖尿病原治疗方案不变,随机均分为两组,对照组口服厄贝沙坦,治疗组在此基础上加用胰激肽原酶。3个月后检测尿白蛋白排泄率变化。结果治疗组和对照组治疗后、各组治疗前后相比较,尿白蛋白排泄率变化有统计学意义(P〈0.01)。结论胰激肽原酶加厄贝沙坦治疗早期糖尿病肾病,可有效减少患者微量白蛋白尿。

关 键 词:2型糖尿病  糖尿病肾病  胰激肽原酶  厄贝沙坦

Effect Observation on Kallidinogenase plus Irbesartan in Treatment of Early Diabetic Nephropathy
Li Taorong,Ning Shangxia,Li Jianying.Effect Observation on Kallidinogenase plus Irbesartan in Treatment of Early Diabetic Nephropathy[J].China Pharmaceuticals,2013(22):26-27.
Authors:Li Taorong  Ning Shangxia  Li Jianying
Institution:( Department of Endocrinology, Jingzhau Municipal Central Hospital, Jingzhou, Hubei, China 434020)
Abstract:Objective To observe the efficacy of kallidinogenase plus irbesartan in treating the patients with early type 2 diabetic nephropathy(DN). Methods 90 cases of early type 2 DN maintained the original diabetic treatment and were randomly divided into 2 groups. The control group took oral irbesartan,while on this basis the treatment group was added with kallidinogenase. The changes of urinary albumin excretion rate (UAER) were examined after 3 months. Results UAER had statistical differences between the treatment group and the control group and between before treatment and after treatment in each group( P 〈 0.01 ). Conclusion Kallidinogenase plus irbesartan in treatin~ early DN can effectively lessen microalbnminuria.
Keywords:type 2 diabetes  diabetic nephropathy  kallidinogenase  irbesartan
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号